These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30176269)

  • 1. 3D human brain cell models: New frontiers in disease understanding and drug discovery for neurodegenerative diseases.
    Korhonen P; Malm T; White AR
    Neurochem Int; 2018 Nov; 120():191-199. PubMed ID: 30176269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons.
    Engle SJ; Blaha L; Kleiman RJ
    Neuron; 2018 Nov; 100(4):783-797. PubMed ID: 30465765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
    Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges.
    Poon A; Zhang Y; Chandrasekaran A; Phanthong P; Schmid B; Nielsen TT; Freude KK
    N Biotechnol; 2017 Oct; 39(Pt B):190-198. PubMed ID: 28579476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
    Corti S; Faravelli I; Cardano M; Conti L
    Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
    Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
    Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
    Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
    Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of human neurons for novel drug discovery in dementia research.
    Vargas-Caballero M; Willaime-Morawek S; Gomez-Nicola D; Perry VH; Bulters D; Mudher A
    Expert Opin Drug Discov; 2016; 11(4):355-67. PubMed ID: 26878555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D Engineering of Ocular Tissues for Disease Modeling and Drug Testing.
    Boutin ME; Hampton C; Quinn R; Ferrer M; Song MJ
    Adv Exp Med Biol; 2019; 1186():171-193. PubMed ID: 31654390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.
    Centeno EGZ; Cimarosti H; Bithell A
    Mol Neurodegener; 2018 May; 13(1):27. PubMed ID: 29788997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
    Struzyna LA; Watt ML
    Mol Pharmacol; 2021 Apr; 99(4):256-265. PubMed ID: 33547249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery.
    Chen SD; Li HQ; Cui M; Dong Q; Yu JT
    Expert Opin Drug Discov; 2020 Sep; 15(9):1081-1094. PubMed ID: 32425128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling neurodegenerative diseases using stem cells: is it accelerating drug discovery?
    Ebert AD
    Future Med Chem; 2012 Sep; 4(13):1651-3. PubMed ID: 22924501
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging three-dimensional neuronal culture assays for neurotherapeutics drug discovery.
    Rathore RS; R Ayyannan S; Mahto SK
    Expert Opin Drug Discov; 2022 Jun; 17(6):619-628. PubMed ID: 35373682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human-Induced Pluripotent Stem Cell-Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases.
    Kiris E
    Adv Exp Med Biol; 2022; 1387():57-88. PubMed ID: 34921676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting.
    Fabre KM; Delsing L; Hicks R; Colclough N; Crowther DC; Ewart L
    Adv Drug Deliv Rev; 2019 Feb; 140():129-135. PubMed ID: 30253201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research on neurodegenerative diseases using induced pluripotent stem cells.
    Imamura K; Inoue H
    Psychogeriatrics; 2012 Jun; 12(2):115-9. PubMed ID: 22712645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells.
    Korecka JA; Levy S; Isacson O
    Mol Cell Neurosci; 2016 Jun; 73():3-12. PubMed ID: 26691153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards Advanced iPSC-based Drug Development for Neurodegenerative Disease.
    Pasteuning-Vuhman S; de Jongh R; Timmers A; Pasterkamp RJ
    Trends Mol Med; 2021 Mar; 27(3):263-279. PubMed ID: 33121873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.